Medicenna Therapeutics Balance Sheet

Financials in millions CAD. Fiscal year is April - March.

Millions CAD. Fiscal year is Apr - Mar.

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar '26 Mar 31, 2026	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022
Cash & Equivalents	6.25	24.84	16.98	33.6	20.54
Cash & Short-Term Investments	6.25	24.84	16.98	33.6	20.54
Cash Growth	-74.83%	46.26%	-49.45%	63.60%	-49.15%
Other Receivables	1.35	2.7	1.16	0.86	1.31
Receivables	1.35	2.7	1.16	0.86	1.31
Prepaid Expenses	0.72	0.64	0.93	1.93	1.55
Total Current Assets	8.32	28.17	19.08	36.39	23.39
Property, Plant & Equipment	0.09	0.16	-	-	-
Other Intangible Assets	0.05	0.05	0.06	0.06	0.07
Total Assets	8.45	28.38	19.13	36.45	23.46
Accounts Payable	4.85	2.7	2.07	1.62	1.67
Accrued Expenses	0.55	1.69	0.79	2.18	0.95
Current Portion of Leases	0.07	0.05	-	-	-
Other Current Liabilities	-	-	-	3.16	-
Total Current Liabilities	5.47	4.44	2.86	6.96	2.62
Long-Term Leases	0.05	0.12	-	-	-
Other Long-Term Liabilities	0.45	4.73	11.08	-	-
Total Liabilities	5.97	9.29	13.94	6.96	2.62
Common Stock	126.26	116.3	100.92	100.92	83.67
Additional Paid-In Capital	12.73	11.22	10.7	9.49	7.93
Retained Earnings	-136.66	-118.25	-106.45	-80.98	-70.93
Comprehensive Income & Other	0.16	9.83	0.02	0.06	0.17
Shareholders' Equity	2.48	19.1	5.19	29.49	20.84
Total Liabilities & Equity	8.45	28.38	19.13	36.45	23.46
Total Debt	0.12	0.17	-	-	-
Net Cash (Debt)	6.13	24.67	16.98	33.6	20.54
Net Cash Growth	-75.14%	45.27%	-49.45%	63.60%	-49.11%
Net Cash Per Share	0.07	0.32	0.24	0.52	0.38
Filing Date Shares Outstanding	92.3	83.38	76.18	69.64	56.3
Total Common Shares Outstanding	83.42	78.22	69.64	69.64	55.65
Working Capital	2.85	23.74	16.21	29.43	20.77
Book Value Per Share	0.03	0.24	0.07	0.42	0.37
Tangible Book Value	2.44	19.04	5.13	29.43	20.77
Tangible Book Value Per Share	0.03	0.24	0.07	0.42	0.37